Abstract
As the pharmacokinetics after a slow infusion had not previously been evaluated in the doses used in this study, it was decided to measure the plasma concentration/time curve after a twelve-hour intravenous infusion of 2·0 g of erythromycin lactobionate in 2 litres of 0·9% normal saline. Six healthy medical students with no past history of cardiovascular, renal, hepatic, metabolic or gastrointestinal disease and no past drug allergy participated. The concentration of erythromycin base in venous blood was measured by small plate microbiological assay. Venous blood was taken at zero, 15, 30, 45, 60 min and at 2, 3, 4, 6, 8, 12, 16, 20 and 24 hr after starting the infusions. Duplicate assays were performed on all plasma samples at Guy's and at the manufacturer's laboratories. A full haematological and biochemical screening profile was performed before and after the study.
The mean ± s.e. plasma erythromycin base concentration rose from 0·7 ± 0·2 μg/ml at 15 min to 6·06 ± 1·6 μg/ml at 1 hr. The peak plasma concentration was between 1·48 ± 0·25 μg/ml at 30 min and 7·21 ± 0·93 μg/ml at 4 hr. The plasma concentration at 12 hr was 6·17 ± 0·33 μg/ml, and fell to 0·37 ± 0·05 μg/ml at 24 hr.
These findings suggest that therapeutically effective plasma concentrations follow a slow intravenous infusion of erythromycin lactobionate. There was no evidence of adverse haematological or biochemical function in the tests of blood, hepatic or renal function, apart from two volunteers who vomited after the infusions were discontinued.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Inadequate antibody response to HBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet. 1974 Dec 28;2(7896):1540–1543. [PubMed] [Google Scholar]
- Neaverson M. A. Intravenous administration of erythromycin: serum, sputum and urine levels. Curr Med Res Opin. 1976;4(5):359–364. doi: 10.1185/03007997609109329. [DOI] [PubMed] [Google Scholar]
- Parsons R. L., Beavis J. P., Hossack G. A., Paddock G. M. Plasma, bone, hip capsule, synovial and drain fluid concentrations of lincomycin during total hip replacement. Br J Clin Pharmacol. 1977 Aug;4(4):433–437. doi: 10.1111/j.1365-2125.1977.tb00758.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Parsons R. L., Beavis J. P., Paddock G. M., David J. A., Trounce J. R. Additives to intravenous fluids. Br Med J. 1976 Nov 20;2(6046):1256–1256. doi: 10.1136/bmj.2.6046.1256-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Parsons R. L., Hossack G., Paddock G. The absorption of antibiotics in adult patients with coeliac disease. J Antimicrob Chemother. 1975 Mar;1(1):39–50. doi: 10.1093/jac/1.1.39. [DOI] [PubMed] [Google Scholar]
- Parsons R. L., Jusko W. J., Young J. M. Pharmacokinetics of antibiotic absorption in coeliac disease. J Antimicrob Chemother. 1976 Jun;2(2):214–215. doi: 10.1093/jac/2.2.214. [DOI] [PubMed] [Google Scholar]
- Roy A. D. The prophylactic use of antimicrobial agents in the surgery of the intestine. J Antimicrob Chemother. 1976 Sep;2(3):233–238. doi: 10.1093/jac/2.3.233. [DOI] [PubMed] [Google Scholar]